Old molecule, new scrutiny: Benzoyl peroxide in dermatology

Clicks: 7
ID: 324929
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #32 of 171 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Benzoyl peroxide (BPO) is a widely available over-the-counter topical medication approved in the 1960s for acne vulgaris treatment. NICE guidelines recommend BPO as a monotherapy or in combination with topical retinoids or antibiotics. However, concerns persist regarding optimal concentration and long-term safety, particularly following recent controversies surrounding benzene formation. Aim To systematically assess evidence on the indications, efficacy, and safety of topical BPO across dermatological conditions. Methodology A literature search following the PRISMA-P guidelines was performed using MEDLINE, Scopus and EMBASE databases from 1992 to 2025. Eligible studies included primary research involving patients with dermatological conditions treated with topical BPO. Primary outcomes were lesion count reduction, investigator global assessment and any treatment-related adverse effects (AEs). Results Of 2347 identified records, 111 articles met the inclusion criteria. BPO monotherapy achieved 75% median lesion reduction versus placebo, with comparable efficacy across concentrations (2.5% vs 5%). Adapalene-BPO combination showed superior outcomes to monotherapy (P<0.001) among 2453 patients, though with increased irritation. Antibiotic-BPO combinations demonstrated 71.3% IGA improvement by week 2 versus 19.3% vehicle control. In rosacea, BPO-clindamycin reduced papules and pustules up to 71%. Local application site reactions, including skin irritation, dryness and bleaching represented the most common AEs. Large population studies demonstrated no significant association between BPO use and detectable blood benzene levels or malignancy risk. Evidence for perioral dermatitis and folliculitis remains limited and heterogenous. Conclusion BPO has a favourable safety profile with predominantly mild, localised AEs. Further randomised controlled trials using validated outcome measures are required to establish efficacy in other dermatological conditions.
Reference Key
openalex_W7202364887 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Allen Lim, Sami Raza, Firas Al-Niaimi, Faisal R. Ali
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag357
URL
https://doi.org/10.1093/ced/llag357
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.